Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-versus-Host Disease Prophylaxis

María Queralt Salas(Canary Institute of Cancer Research), Auro Viswabandya(Princess Margaret Cancer Centre), Jeffrey H. Lipton(Princess Margaret Cancer Centre), David Loach(University Health Network), Rajat Kumar(University Health Network), Arjun Law(University of Toronto), Santhosh Thyagu(Princess Margaret Cancer Centre), Fotios V. Michelis(Princess Margaret Cancer Centre), Jonas Mattsson(University Health Network), Zeyad Al‐Shaibani(University Health Network), Wilson Lam(Princess Margaret Cancer Centre), Dennis Kim(Princess Margaret Cancer Centre)
Clinical Hematology International
January 1, 2019
10.2991/chi.d.190316.003
Cited by 25

Related Papers

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
|Cancer Cell|2014|366
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
|Leukemia|2008|354
A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
|Oncotarget|2017|187
Troglitazone but not Metformin Restores Insulin-Stimulated Phosphoinositide 3-Kinase Activity and Increases p110β Protein Levels in Skeletal Muscle of Type 2 Diabetic Subjects
|Diabetes|2002|129
Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies
|Biology of Blood and Marrow Transplantation|2018|92